	US 12,391,736 B2
	Off-the-shelf cancer vaccines
Ronald Hans Anton Plasterk, Amsterdam (NL)
Assigned to CureVac Netherlands B.V., Amsterdam (NL)
Appl. No. 17/262,917
Filed by CureVac Netherlands B.V., Amsterdam (NL)
PCT Filed Jul. 25, 2019, PCT No. PCT/NL2019/050491 § 371(c)(1), (2) Date Jan. 25, 2021, PCT Pub. No. WO2020/022898, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 2021400 (NL), filed on Jul. 26, 2018; and application No. 2022447 (NL), filed on Jan. 24, 2019.
Prior Publication US 2021/0238244 A1, Aug. 5, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 39/00 (2006.01); C07K 5/083 (2006.01); C07K 7/08 (2006.01); C12Q 1/6886 (2018.01)

CPC C07K 14/4748 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001151 (2018.08); C07K 5/0808 (2013.01); C07K 7/08 (2013.01); C12Q 1/6886 (2013.01); A61K 39/00 (2013.01); A61K 2039/645 (2013.01); C07K 2319/00 (2013.01); C12Q 2600/156 (2013.01)]

3 Claims

1. A peptide comprising at least two amino acid sequences, wherein each of said at least two amino acid sequences is independently selected from the group consisting of SEQ ID NOS: 601 to 605, or an isolated nucleic acid comprising a nucleotide sequence encoding said peptide.